Biotechnological approaches for sustainable production of astragaloside I, II and IV from endemic species of Astracantha aitosensis (Ivan.) and Astragalus membranaceus (fisch.) by in vitro cultures

IF 1.1 Q4 PHARMACOLOGY & PHARMACY Pharmacia Pub Date : 2023-11-30 DOI:10.3897/pharmacia.70.e114989
Preslav Enchev, Y. Zarev, I. Ionkova
{"title":"Biotechnological approaches for sustainable production of astragaloside I, II and IV from endemic species of Astracantha aitosensis (Ivan.) and Astragalus membranaceus (fisch.) by in vitro cultures","authors":"Preslav Enchev, Y. Zarev, I. Ionkova","doi":"10.3897/pharmacia.70.e114989","DOIUrl":null,"url":null,"abstract":"This study investigates the bioproduction of astragalosides I, II and IV from endemic Astracantha aitosensis (arnacantha) and Astragalus membranaceus species, and the biotechnological methods for increased efficiency. The extracts from established in vitro cultures, including A. aitosensis callus, shoots and roots and A. membranaceus hairy roots, showed higher astragaloside concentrations than native roots. Specifically, in vitroA. aitosensis cultures produced astragaloside I and II at 0.06 and 0.10 mg/g DW, which were absent in native roots. The production of A. membranaceuss hairy roots exceeds 8 to 15 times astragaloside I and II (0.80 and 0.90 mg/g DW) production when compared to native roots (0.10 and 0.05 mg/g DW), and around 3 times high amount related to astragaloside IV. Addressing astragaloside production challenges, this research also reveals biotechnology approaches as an alternative for sustainable production of this rare cycloartane saponins, conserving the natural habitats. A pilot reproducible in vitro cellular platform has been created, and protocol for specific, unconventional induction of the biosynthesis of the desired target compounds, exploiting the enzymatic system of plant cells from the unexplored plant species A. aitosensis has been established. Our findings clearly show the possibility of using in vitro cultures of A. aitosensis and A. membranaceus for biotechnology production of cycloartane type saponins.","PeriodicalId":20086,"journal":{"name":"Pharmacia","volume":"10 1","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3897/pharmacia.70.e114989","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

This study investigates the bioproduction of astragalosides I, II and IV from endemic Astracantha aitosensis (arnacantha) and Astragalus membranaceus species, and the biotechnological methods for increased efficiency. The extracts from established in vitro cultures, including A. aitosensis callus, shoots and roots and A. membranaceus hairy roots, showed higher astragaloside concentrations than native roots. Specifically, in vitroA. aitosensis cultures produced astragaloside I and II at 0.06 and 0.10 mg/g DW, which were absent in native roots. The production of A. membranaceuss hairy roots exceeds 8 to 15 times astragaloside I and II (0.80 and 0.90 mg/g DW) production when compared to native roots (0.10 and 0.05 mg/g DW), and around 3 times high amount related to astragaloside IV. Addressing astragaloside production challenges, this research also reveals biotechnology approaches as an alternative for sustainable production of this rare cycloartane saponins, conserving the natural habitats. A pilot reproducible in vitro cellular platform has been created, and protocol for specific, unconventional induction of the biosynthesis of the desired target compounds, exploiting the enzymatic system of plant cells from the unexplored plant species A. aitosensis has been established. Our findings clearly show the possibility of using in vitro cultures of A. aitosensis and A. membranaceus for biotechnology production of cycloartane type saponins.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
通过体外培养从黄芪和黄芪膜(鱼腥草)的特有种中可持续生产黄芪皂苷 I、II 和 IV 的生物技术方法
本研究探讨了从当地特有的黄芪(Astracantha aitosensis,arnacantha)和黄芪(Astragalus membranaceus)物种中生物生产黄芪皂苷 I、II 和 IV,以及提高效率的生物技术方法。从已建立的体外培养物(包括黄芪胼胝体、芽和根以及膜荚黄芪毛根)中提取的黄芪皂苷浓度高于原生根。具体来说,A. aitosensis 体外培养物产生的黄芪皂苷 I 和 II 的含量分别为 0.06 和 0.10 毫克/克(干重),而本地根中则没有。与本地根(0.10 和 0.05 毫克/克 DW)相比,A. membranaceuss 发根的黄芪皂苷 I 和 II 产量(0.80 和 0.90 毫克/克 DW)超过 8 至 15 倍,黄芪皂苷 IV 的产量也高出 3 倍左右。针对黄芪皂苷生产面临的挑战,这项研究还揭示了一种生物技术方法,可用于可持续生产这种稀有的环木菠萝烷皂苷,保护自然栖息地。我们建立了一个试验性可重复体外细胞平台,并制定了利用未开发植物物种 A. aitosensis 植物细胞的酶系统,特异性地、非传统地诱导所需目标化合物生物合成的方案。我们的研究结果清楚地表明,有可能利用艾托斯草(A. aitosensis)和膜草(A. membranaceus)的体外培养物进行环木菠萝烷类皂甙的生物技术生产。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmacia
Pharmacia PHARMACOLOGY & PHARMACY-
CiteScore
2.30
自引率
27.30%
发文量
114
审稿时长
12 weeks
期刊最新文献
Microneedle and drug delivery across the skin: An overview Nephroprotective effects of Equisetum ramosissimum L. extract in streptozotocin-induced diabetic rats Spectroscopic and thermodynamic characterization of the interaction of a new synthesized antitumor drug candidate 2H4MBBH with human serum albumin Amstirdam coffee ameliorates Lp-PLA2 and the inflammatory response in an atherosclerosis rats A 36-year-old woman with a parathyroid cyst
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1